Finanzen von Bolt Biotherapeutics, Inc. (BOLT)BOLTBolt Biotherapeutics, Inc.

Evaluating the bottom line, Bolt Biotherapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -151320.00%, while the net margin is -154400.00%. These profitability ratios, combined with a Return on Equity (ROE) of -111.65%, provide a clear picture of how effectively BOLT converts its operational activities into shareholder value.

In the context of the broader market, BOLT competes directly with industry leaders such as ERNA and ACXP. With a market capitalization of $7.67M, it holds a leading position in the sector. When comparing efficiency, BOLT's gross margin of 100.00% stands against ERNA's N/A and ACXP's N/A. Such benchmarking helps identify whether Bolt Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% across recent quarters, indicating strong pricing power despite revenue challenges. However, net income remains negative, with a significant loss of -7.72 million in Q2 2026, which raises concerns about profitability.